Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jan 14;16(1):e0245085.
doi: 10.1371/journal.pone.0245085. eCollection 2021.

Viral load care of HIV-1 infected children and adolescents: A longitudinal study in rural Zimbabwe

Tichaona Mapangisana  1 , Rhoderick Machekano  1   2 , Vinie Kouamou  3 , Caroline Maposhere  4 , Kathy McCarty  5 , Marceline Mudzana  5 , Shungu Munyati  4 , Junior Mutsvangwa  4 , Justen Manasa  6   7 , Tinei Shamu  8   9 , Mampedi Bogoshi  10 , Dennis Israelski  10 , David Katzenstein  4   11
Affiliations
Clinical Trial

Viral load care of HIV-1 infected children and adolescents: A longitudinal study in rural Zimbabwe

Tichaona Mapangisana et al. PLoS One. .

Abstract

Introduction: Maintaining virologic suppression of children and adolescents on ART in rural communities in sub-Saharan Africa is challenging. We explored switching drug regimens to protease inhibitor (PI) based treatment and reducing nevirapine and zidovudine use in a differentiated community service delivery model in rural Zimbabwe.

Methods: From 2016 through 2018, we followed 306 children and adolescents on ART in Hurungwe, Zimbabwe at Chidamoyo Christian Hospital, which provides compact ART regimens at 8 dispersed rural community outreach sites. Viral load testing was performed (2016) by Roche and at follow-up (2018) by a point of care viral load assay. Virologic failure was defined as viral load ≥1,000 copies/ml. A logistic regression model which included demographics, treatment regimens and caregiver's characteristics was used to assess risks for virologic failure and loss to follow-up (LTFU).

Results: At baseline in 2016, 296 of 306 children and adolescents (97%) were on first-line ART, and only 10 were receiving a PI-based regimen. The median age was 12 years (IQR 8-15) and 55% were female. Two hundred and nine (68%) had viral load suppression (<1,000 copies/ml) and 97(32%) were unsuppressed (viral load ≥1000). At follow-up in 2018, 42/306 (14%) were either transferred 23 (7%) or LTFU 17 (6%) and 2 had died. In 2018, of the 264 retained in care, 107/264 (41%), had been switched to second-line, ritonavir-boosted PI with abacavir as a new nucleotide analog reverse transcriptase inhibitor (NRTI). Overall viral load suppression increased from 68% in 2016 to 81% in 2018 (P<0.001).

Conclusion: Viral load testing, and switching to second-line, ritonavir-boosted PI with abacavir significantly increased virologic suppression among HIV-infected children and adolescents in rural Zimbabwe.

PubMed Disclaimer

Conflict of interest statement

The authors have read the journal’s policy and the authors of this manuscript have the following competing interests: DI and MB are paid employees of Gilead Sciences Inc. There are no patents, products in development or marketed products to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Hurungwe district in Northwestern Zimbabwe.
A-map of the Southern part of Africa showing Zimbabwe and surrounding countries; B-map of Zimbabwe showing the Hurungwe District in the Northwestern part of Zimbabwe. The approximate location of Chidamoyo Christian Hospitalis indicated by the white star and the relative locations of five outpatient sites (Batanayi, Magororo, Chedope, Nyamutora, and Zvarai) are indicated by white circles; C-the arrow is pointing to Chidamoyo Christian Hospital. This figure was downloaded online from the Humanitarian Response info website (https://www.humanitarianresponse.info/sites/www.humanitarianresponse.info/files/ZWE).
Fig 2
Fig 2. Longitudinal assessment of viral load measures at baseline and after 18 months of follow-up among 264 children and adolescents.
The regimen changes (from non-nucleoside reverse transcriptase inhibitor to protease inhibitor-based combinations) were based on the Zimbabwe guidelines on formulations, dosing, toxicities, and availability of combination ART in 2017. Virologic failure (≥1,000 copies/ml) at enrollment and follow-up are indicated in red.
See this image and copyright information in PMC

References

    1. Hayes Richard, Floyd Sian, Schaap Ab, Shanaube Kwame, Bock Peter, Sabapathy Kalpana, et al. A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial [Internet]. [cited 2019. September 23]. Available from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1... - PMC - PubMed
    1. Mark D, Armstrong A, Andrade C, Penazzato M, Hatane L, Taing L, et al. HIV treatment and care services for adolescents: a situational analysis of 218 facilities in 23 sub-Saharan African countries. Journal of the International AIDS Society. 2017;20(S3):21591 10.7448/IAS.20.4.21591 - DOI - PMC - PubMed
    1. Agwu AL, Fairlie L. Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents. Journal of the International AIDS Society. 2013. January 1;16(1):18579. - PMC - PubMed
    1. Mutanga JN, Mutembo S, Ezeamama AE, Song X, Fubisha RC, Mutesu-Kapembwa K, et al. Long-term survival outcomes of HIV infected children receiving antiretroviral therapy: an observational study from Zambia (2003–2015). BMC Public Health. 2019. January 28;19(1):115 10.1186/s12889-019-6444-7 - DOI - PMC - PubMed
    1. Kariminia A, Law M, Davies M-A, Vinikoor M, Wools‐Kaloustian K, Leroy V, et al. Mortality and losses to follow-up among adolescents living with HIV in the IeDEA global cohort collaboration. Journal of the International AIDS Society. 2018;21(12):e25215 10.1002/jia2.25215 - DOI - PMC - PubMed

Publication types

Substances